IL-6 and related cytokines as the critical lynchpins between inflammation and cancer

Highlights • The IL-6 family of cytokines includes IL-6, IL-11, IL-27, IL-31, LIF, OSM, CNTF, CT-1 and CLC. • The IL-6 family of cytokines regulates cell proliferation, survival, migration, invasion, metastasis, angiogenesis and inflammation via gp130. • The JAK-STAT3 pathway is the major pathway do...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in immunology 2014-02, Vol.26 (1), p.54-74
Main Authors: Taniguchi, Koji, Karin, Michael
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Colorectal cancer
Cytokines - genetics
Cytokines - metabolism
Gastric cancer
gp130
Hepatocellular carcinoma
Humans
IL-11
IL-6
Inflammation - genetics
Inflammation - immunology
Inflammation - metabolism
Interleukin-6 - genetics
Interleukin-6 - metabolism
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - pathology
Neovascularization, Pathologic
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Receptors, Interleukin-6 - antagonists & inhibitors
Receptors, Interleukin-6 - metabolism
Signal Transduction - drug effects
STAT3
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The IL-6 family of cytokines includes IL-6, IL-11, IL-27, IL-31, LIF, OSM, CNTF, CT-1 and CLC. • The IL-6 family of cytokines regulates cell proliferation, survival, migration, invasion, metastasis, angiogenesis and inflammation via gp130. • The JAK-STAT3 pathway is the major pathway downstream of gp130 signaling. • IL-6 and IL-11 are highly up-regulated in many cancers and are important mediators linking inflammation and cancer. • IL-6 and IL-11 are potential therapeutic and preventive targets as well as prognostic factors in cancer.
ISSN:1044-5323
1096-3618
DOI:10.1016/j.smim.2014.01.001